Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic for Adult Patients with Myelofibrosis


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic for Adult Patients with Myelofibrosis
If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Inrebic (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase(JAK) inhibitor naïve or have been treated with ruxolitinib. The CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, Inrebic will be the first, once-daily oral therapy to significantly reduce spleen volume and symptom burden for patients with myelofibrosis where treatment with ruxolitinib has failed or who are JAK inhibitor naïve.

The CHMP adopted a positive opinion based on results from the JAKARTA and JAKARTA2 studies. The pivotal JAKARTA study evaluated the efficacy of once-daily oral doses of Inrebic compared with placebo in 289 patients with intermediate-2 or high-risk primary or secondary myelofibrosis with splenomegaly.1 The JAKARTA2 study evaluated the efficacy of once-daily oral doses of Inrebic in 97 patients with intermediate or high-risk primary or secondary myelofibrosis with splenomegaly previously treated with ruxolitinib.2

“For nearly a decade, patients with myelofibrosis who have progressed on ruxolitinib have had no treatment options for this rare bone marrow disorder, characterized by debilitating symptoms and an enlarged spleen,” said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb. “The positive CHMP opinion for Inrebic reinforces our commitment to improving on standards of care for patients living with hard-to-treat blood diseases and we look forward to the European Commission’s decision.”

The EC is expected to deliver its final decision within 67 days of receipt of the CHMP opinion. The decision will be applicable to all EU member states and Iceland, Norway and Liechtenstein.

Inrebic is approved in the United States for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 In Canada, Inrebic is approved for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.3

In the clinical development program of Inrebic, which included 608 patients, serious and fatal cases of encephalopathy, including Wernicke’s, occurred in Inrebic-treated patients. Serious cases were reported in 1.3% (8/608) of patients treated with Inrebic in clinical trials and 0.16% (1/608) of cases were fatal.

Tags : #LatestPharmaNewsDec11 #LatestBristolMyersSquibbNewsDec11 #TreatmentforMyelofibrosis

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026
Advanced Navigation Systems in Neurosurgery: Precision TechNovember 11, 2026
Ambient Computing in Healthcare: India's Invisible Tech RevolutionNovember 11, 2026
World Diabetes Day 2026, ‘Early Action on Diabetes,’November 10, 2026
Gulf Medical University Celebrates 28 Years: Born in Thumbay, Built at GMUNovember 10, 2026
Patient Safety Is a Business Priority for Indian HospitalsNovember 10, 2026
Reducing ED Wait Times Through Smarter Hospital DesignNovember 10, 2026